WASHINGTON - The Food and Drug Administration is investigating reports of liver damage in patients taking alli, the only nonprescription weight-loss drug approved by the agency.
Regulators said yesterday they have received more than 30 reports of liver damage in patients taking alli and Xenical, the prescription version of the drug. The reports, submitted between 1999 and October 2008, included 27 hospitalized patients and six who suffered liver failure.
Alli and Xenical are both marketed by British drugmaker
The FDA says it has not established a direct relationship between the weight-loss treatments and liver injury, and advised patients to continue using the drugs as directed.
The FDA said signs of liver damage include fatigue, fever, nausea, and vomiting.